U.S. Markets close in 5 hrs 22 mins

Why This Biotech Stock Is Defying A Hematology-Related Pitfall

ALLISON GATLIN
Why This Biotech Stock Is Defying A Hematology-Related Pitfall

GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer drug data.